Convatec sustainability score: 39/100

·Healthcare / Pharmaceuticals·Reading, United Kingdom·Founded 1978·Last verified 29 August 2026
39
out of 100
Below expectationsPending ReviewMixed evidence· 10 src

Convatec scores 39/100 (Below expectations) on SINK's independent climate assessment — scored from public data only, no company payment can change a number. Last verified August 2026.

That places Convatec joint 290th of 650 companies scored, and joint 11th of 14 in Healthcare / Pharmaceuticals.

Convatec has achieved credible operational carbon reductions (62% Scope 1+2 by 2024) backed by SBTi validation, but Scope 3—representing 94% of footprint—targets intensity, not absolute cuts. Water and biodiversity impacts are identified but unquantified. Transparency is strong; controversies absent.

Is this your company?

This score is built from public data only. If your practice is stronger than your disclosure, submit evidence for review — or challenge any question, free.

Enhanced Assessment — £99
The calculation

How is Convatec's SINK score calculated?

Same formula for every company. No curve. No private weighting.

SINK = (0.3 × Base + 0.7 × Performance) × Scale
Industry base impact
Healthcare / Pharmaceuticals sector ceiling.
45 / 100
Performance score
Sum of the 10 rubric questions, scored 0–10 each.
60 / 100
Raw score
Weighted average before scale penalty.
(0.3 × 45) + (0.7 × 60) = 55.5
Scale penalty
Multiplier based on absolute emissions volume — physics-first.
× 0.7
Final score
Rounded. Below expectations.
39 / 100
The ten questions

What is Convatec doing well, and where does it fall short?

Strongest on Controversies & Red Flags and Carbon Footprint — Operations (8/10, 7/10). Weakest on Water Impact and Nature & Biodiversity Impact (4/10, 4/10).

Where the evidence comes from

What evidence is Convatec's score based on?

10 sources used in this assessment. All publicly available. Each row shows which rubric questions it informed.

[1]Self-reported
Sustainability — Environment

In 2024, we reduced our Scope 1 and 2 GHG emissions by 14% against our 2023 emissions

Ongoing
Q1Q2Q3Q4Q5Q6Q7Q9
View →
[2]Self-reported
About Us — Governance — Documents and Disclosures

2024 Independent assurance report PDF · ESG Basis of reporting FY24 PDF

Ongoing
Q1Q5Q6Q9
View →
[3]Self-reported
Protecting the Planet and Supporting Communities

In 2024, we reached 62% reduction against the baseline, achieved through improved energy efficiency, retrofits, smart metering

Ongoing
Q1Q2Q3Q4Q8
View →
[4]Self-reported
ESG Basis of Reporting FY23

screening exercise during 2022 to determine which of the Scope 3 categories are most significant

2023
Q2
View →
[5]Self-reported
NHS Carbon Reduction Plan 2024

Science Based Target, which was validated in 2023

2024
Q7Q8
View →
[6]Public record
Convatec FY24 Results — Investegate

B-rating from the Carbon Disclosure Project (CDP) and a Silver award from EcoVadis in their 2024 ratings

2024
Q9
View →
[7]Self-reported
Annual Report 2025

reducing Scope 1 and 2 greenhouse gas emissions by 6.9% and procuring over 99% of its electricity from renewable sources globally

2025
Q3Q4
View →
[8]Third-party verified
SBTi Target Dashboard

The SBTi's Target Dashboard lists companies and financial institutions that have set science-based targets, or have committed to developing targets.

Ongoing
Q8
View →
[9]Third-party verified
InfluenceMap Climate Lobbying Database

the majority of industrial companies in sectors like retail and healthcare not strategically involved in climate policy

Ongoing
Q10
View →
[10]Public record
Convatec — Wikipedia

In 2023, ConvaTec was included in the 'Leave Russia' project, which tracks companies that remain active in the Russian market

Ongoing
Q10
View →

If you believe a source has been misread or a newer version exists, submit a challenge.

Convatec in context

How does Convatec compare with other healthcare / pharmaceuticals companies?

Convatec is tied at the bottom of the healthcare / pharmaceuticals pack.

Among the 14 major healthcare / pharmaceuticals brands we've scored, Convatec is tied =11th of 14, with 3 others.

=11/14
Convatec's rank
46
Industry average
39
Industry low
52
Industry high
How this score has moved

Has Convatec's score changed?

today

Score history begins .

As Convatec's score updates, the trajectory will appear here.

We're backfilling historical scores for FTSE 100 and S&P 100 companies over the coming weeks.

What's being contested

Has Convatec's score been challenged?

This score is not currently being contested.

Every challenge is published. We'd rather be corrected than wrong — that's the whole point.

No challenges submitted yet. If you have evidence that contradicts this score, you can challenge any question above — cite a public source and we'll review it.

About Convatec

Convatec is a Reading-based medical device manufacturer specializing in ostomy care, continence and infusion therapies, and wound care. Founded 1978, listed on NASDAQ. Operates global manufacturing and distribution networks serving healthcare systems and patients across 100+ countries.

Founded
1978
Headquarters
Reading, United Kingdom
Employees
~10,000
Annual revenue
~$2.28B
Company website ↗
Track Convatec

We'll let you know when the score moves.

Email alerts when a rubric question is verified, a challenge is resolved, or the overall score changes.

THE SUNDAY RUNDOWN

Which companies moved this week, and why.

One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.

No spam. Unsubscribe in one click.

HOW SINK STAYS INDEPENDENT

Readers and institutions support our work. Companies can pay to submit evidence we couldn't find. Neither type of payment changes a score.